Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 2, 2001 - Issue 6
Submit an article Journal homepage
228
Views
21
CrossRef citations to date
0
Altmetric
Drug Evaluation

Infliximab

Emil Valle The Digestive Health Center, 800708 University of Virginia Health System, Charlottesville, VA 22908, USA
,
Stephen J Bickston The Digestive Health Center, 800708 University of Virginia Health System, Charlottesville, VA 22908, USA
&
Meredith Gross The Digestive Health Center, 800708 University of Virginia Health System, Charlottesville, VA 22908, USA
Pages 1015-1025 | Published online: 24 Feb 2005

Bibliography

  • BREEDVELD FC: Therapeutic monoclonal antibodies. Lancet (2000) 355:735–740.
  • •General review of mAbs.
  • SARTOR RB: Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology (1994) 106:533–539.
  • PAPADAKIS KA, TARGAN SR: Role of cytokines in the pathogenesis of Inflammatory bowel disease. Ann. Rev Med. (2000) 51:289–298.
  • •Review of cytokine involvement in IBD.
  • LICHTENSTEIN GR: Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment. Cur. Opin Gastroen (2000) 16:83–88.
  • SCHREIBER S: Inflammatory bowel disease: immunologic concepts. Hepato-Gastroenterology (2000) 47:15–28.
  • DINARELLO C: Pro-inflammatory cytokines. Chest (2000) 118:503–508.
  • ••Good review of inflammatory cytokines.
  • KSONTINI R, MACKAY SLD, MOLDAWER LL: Revisiting the role of tumour necrosis factor a and the response to surgical injury and inflammation. Arch. Surg. (1998) 133:558–567.
  • VAN DEVENTER SJH: Review article: targeting TNF-a as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment. Pharmacy]. Ther. (1999) 13\(Suppl. 4):3–8.
  • •Review of proposed mechanisms for infliximab efficacy.
  • LUSTER MI, SIMEONOVA PE GALLUCCI R, MATHESON J: Tumour necrosis factor alpha and toxicology. Grit. Rev. Tax. (1999) 29(5):491–511.
  • BEUTLER BA: The role of tumour necrosis factor in health and disease. Rheumatal (1999) 26\(Suppl. 57):16–21.
  • ••Good review of TNF biology.
  • MOUSER JF, HYAMS JS: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin. Ther. (1999) 21(6):932–942.
  • ••Good review of infliximab.
  • BELL S, KAMM MA: Antibodies to tumour necrosis factor [alpha] as treatment for Crohn's disease. Lancet (2000) 355(9207):858–860.
  • BELL SJ, KAMM MA: Review article: the clinical role of antiTNFa antibody treatment in Crohn's disease. Aliment. Pharmacy]. Ther. (2000) 14:501–514.
  • STACK WA, MANN SD, ROY AJ et al: Randomised controlled trial of CDP571 antibody to tumour necrosis factor - alpha in Crohn's disease. Lancet (1997) 349(9050:521–524.
  • RANKIN EC, CHOY EH, KASSIMOS D et al: The therapeutic effects of an engineered human antitumour necrosis factor alpha antibody CDP571 in rheumatoid arthritis. Br j Rheumatal (1995) 34(4):334–342.
  • FOX DA: Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumour necrosis factor. Arch. Intern. Med. (2000) 160:437–444.
  • •Review of cytokines in RA.
  • MODER KG: New medications for use inpatients with rheumatoid arthritis. Ann. Allergy Asthma Immunal (2000) 84:280–287.
  • D'HAENS G, SWUSEN C, NOMAN M, LEMMENS L, GEBOES K, RUTGEERTS P: Etanercept (TNF receptor fusion protein, Enbrelq is effective and well-tolerated in active refractory Crohn's disease: results of a single center pilot trial. Digestive Disease Week, San Diego, USA (2000) Abstract no. 3600.
  • VAN OOSTEN BW, BARKHOF TRUYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumour necrosis factor antibody cA2. Neurology (1996) 47:1531–1534.
  • EHRENPREIS ED, SUNANDA KV, COHEN LB, COHEN RD, HANAUER SB.: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271–1277.
  • MURTHY S, COOPER HS, YOSHITAKE H, MEYER C, MEYER CJ, MURTHY NS: Combination therapy of pentoxifylline and TNF alpha monoclonal antibody in dextran sulfate-induced mouse colitis. Aliment. Pharmacy]. Ther. (1999) 13(2):251–260.
  • ISHII O, YAMADA H, OHYA S et al: Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis. Ryumachl (1997) 37(6):810–815.
  • PIETRO GA, FRIEDMAN LS: Epidemiology and the natural course of inflammatory bowel disease. Intlama Bowel Dis. (1999) 28(2):255–281.
  • STEIN RB, HANAUER SB: Medical therapy for inflammatory bowel disease. Gastroenterology Clinics of North America. (1999) 28(2):297–318.
  • ••Good review of IBD.
  • RUTGEERTS PJ: Review article: efficacy of infliximab in Crohn's disease - induction and maintenance of remission. Aliment. Pharmacol. Ther. (1999) 13\(Suppl. 4):9–15.
  • PRESENT DH: Review article: the efficacy of infliximab in Crohn's disease - healing of fistulae. Ailment. Pharmacol Ther. (1999) 13\(Suppl. 4):23–28.
  • WEYAND CM: New insights into the pathogenesis of rheumatoid arthritis. Rheumatology (2000) 39\(Supp1.1):3–8.
  • FOX DA: Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumour necrosis factor. Arch. Intern. Med. (2000) 160:437–444.
  • MAINI RN, VANDERHEIJDE D, EMERY P et al.: Sustained clinical benefit and arrest of radiologic joint damage in patients with active rheumatoid arthritis treated with infliximab along with methotrexate (ATTRACT trial). European League Against Rheumatism. Nice, France (2000). Abstract no. OP–005.
  • ••Study demonstrating improvement of jointdamage following infliximab therapy.
  • SANDS BE, POD OLSKY DK, TREMAINE WJ et al.: Chimeric monoclonal antitumour necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis. Gastroenterology (1996) 110:A1008. Abstract.
  • OH CJ, DAS KM, GOTTLIEB AB: Treatment with antitumour necrosis factor a (TNF-a) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. j Am. Acad. Dermatol (2000) 42:829–830.
  • SILWA K, SKUDICKY D, CANDY G, WISENBAUGH T, SARELI P: Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet (1998) 351:1091–1093.
  • DESWAL A, BOZKURT B, SETA Y et al: Safety and efficacy of a soluble P75 tumour necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224–3226.
  • HICKS K, IPPOLITI C, DONATO M et al.: Infliximab for the treatment of steroid refractory graft versus host disease in allogeneic transplant recipients. American Socie0, of Hematology Annual Meeting (1999) Abstract no. 680.
  • CENTOCOR, INC.: Remicade (infliximab) data sheet (Nov 1999).
  • KNIGHT DM, HAN T, JUNMING L et al.: Construction and initial characterization of a mouse-human chimeric antiTNF antibody. Mol Immunol (1993) 30(16):1443–1453.
  • ••Molecular biology of infliximabdevelopment.
  • CENTOCOR - data on file.
  • CENTOCOR, INC.: Remicade IV infusion instructions. (Nov 1999).
  • NAKADA MT, TAM SH, WOULFE DS, CASPER KA, SWERLICK RA, GHRAYEB J: Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes. Commun. (1998) 5(6):491–503.
  • VANDEVENTER SJH: Immunotherapy of Crohn's disease. Scant/. j Immunol (2000) 51:18–22.
  • VANDEVENTER SJH: AntiTNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. (1999) 58 (Suppl. 1):114–120.
  • HAY AR, HAY JW: Inflammatory bowel disease: medical cost algorithms. I Chit. Gastroenterol (1992) 14:318–327.
  • •Economic impact of IBD.
  • CALLAHAN LF: The burden of rheumatoid arthritis: facts and figures. Rheumatol. (1992) 25:8–12.
  • YELIN E, WANKE LA: An assessment of the annual and long-term direct costs of rheumatoid arthritis. Arth. Rheum. (1999) 42:1209–1218.
  • ••Economic impact of RA.
  • FEAGAN BG: Review article: economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life. Aliment. Pharmacol. Ther. (1999) 13\(Suppl. 4):29–37.
  • LANES SF, LANZA LL, RADENSKY PW etal.: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum. (1997) 40:1475–1481.
  • HANAUER SB, COHEN RD, BECKER RV, LARSON LR, VREELAND MG: Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin. Ther. (1998) 20:1009–1027.
  • SINGLETON JW, LAW DH, KELLEY ML Jr., MEKHJIAN HS, STURDEVANT RA: National co-operative Crohn's disease study: adverse reactions to study drugs. Gastroenterology (1979) 77:870–882.
  • Infliximab (Remicade) for Crohn's disease. The Medical Letter (1999) 41:19–20.
  • COHEN RD, LARSON LR, ROTH JM, BECKER RV, MUMMER LL: The cost of hospitalization in Crohn's disease. Amer. Gastroenterol (1999) 95:524–530.
  • BEST WR, BEKTEL JM, SINGLETON JW, KERN F: Development of a Crohn's disease activity index. Gastroenterology (1976) 70:439–444.
  • HOCHBERG MC, CHANG RW, DWOSH I et al: The American college of rheumatology 1991 revised criteria for the classification of global function status in rheumatoid arthritis. Arthritis Rheum. (1992) 35:498–502.
  • VAN DULLEMEN HM, VAN DEVENTER SJH, HOMMES DW etal.: Treatment of Crohn's disease with antitumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
  • MCCABE RP WOODY J, VANDEVENTER S etal.: A multicenter trial of cA2 antiTNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology (1996) 110:A962. Abstract.
  • ELLIOT MJ, MAINI RN, FELDMANN Metal.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor a. Arthritis Rheum. (1993) 36:1681–1690.
  • TARGAN SR, HANAUER SB, VANDEVENTER SJH et al: A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor a for Crohn's disease. N Engl. J. Med. (1997) 337:1029–1035.
  • RUTGEERTS P, D'HAENS G, VANDEVENTER SJH et al: Retreatment with antiTNF-a chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Digestive Disease Week. Washington DC, USA (1997). Abstract no. 47.
  • D'HAENS G, VANDEVENTER S, VANHOGEZAND R et al.: Endoscopic and histologic healing with infliximab antitumour necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology (1999) 116:1029–1034.
  • •Study assessing endoscopic and histological improvement after infliximab treatment.
  • PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N El .j Med. (1999) 340:1398–1405.
  • ••Study using infliximab to treat fistulas inCD.
  • ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
  • MAINI RN, BREEDVELD FC, KALDEN JR: Therapeutic efficacy of multiple iv. infusions of antitumour necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41(9):1552–1563.
  • RAVINDER M, STCLAIR EW, BREEDVELD F: Infliximab (chimeric anti tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet (1999) 354:1932–1939.
  • ••Largest study of infliximab for RA.
  • HANAUER SB: Review article: safety of infliximab in clinical trials. Aliment. Pharmacol. Ther. (1999) 13\(Suppl. 4):16–22.
  • ••Review of infliximab safety and sideeffects.
  • BICKSTON SJ, LICHTENSTEIN GR, ARSENEAU KO, COHEN RB, COMINELLI F: The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology (1999) 117:1433–1437.
  • •Review of lymphoma in infliximab-treated patients.
  • KORNBLUTH A: Infliximab approved for use in Crohn's disease: a report on the FDA GI advisory committee conference. Billamm. Bowel Dis. (1998) 4:328–329.
  • KAM LY, VASILIAUSKAS EA, LANDERS CJ, TARGAN SR: Magnitude of response to RemicadeTm correlates with marker antibody expression. Digestive Disease Week, San Diego, USA (2000) G3232.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.